Treating Cardiopulmonary Disease with Inhaled Targeted Therapies

Pulmonary arterial hypertension is a rare and progressive condition characterized by high blood pressure in the arteries of the lungs due to their narrowing or a blockage. This causes the heart to work harder to pump blood and leads to heart failure, the need for lung transplantation, and death. Aerami is developing an inhaled form of the targeted cancer therapy imatinib as a treatment for PAH. We spoke to Josh Ziel, chief operating officer and interim CEO of Aerami, about pulmonary arterial hypertension, the company’s experimental therapy to treat the condition, and its efforts to build a pipeline of therapies that make use of its proprietary inhalation technology.